Positive Phase 3 Results for Jazz Pharmaceuticals' Zepzelca and Tecentriq Combo in ES-SCLC Treatment

Jazz Pharmaceuticals plc has announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) for maintenance treatment in adults with extensive-stage small cell lung cancer (ES-SCLC). The trial compared the combination therapy to atezolizumab alone following induction therapy with carboplatin, etoposide, and atezolizumab. The Zepzelca and atezolizumab combination showed a statistically significant improvement.

Publish Date: 15-10-2024 Source: Jazz Pharmaceuticals plc

Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid and widespread growth, making it one of the most lethal forms of cancer. Unlike limited-stage SCLC (LS-SCLC), which has not yet metastasized and can potentially be cured, ES-SCLC is not curable. ES-SCLC is characterized by widespread lung tumor growth, involvement of the other lung, lymph nodes on the opposite side of the chest, or other parts of the body. It may also extend to the fluid surrounding the lungs. Due to its rapid and early metastasis, most individuals with small-cell lung cancer are diagnosed with extensive-stage disease before symptoms become apparent. In most cases, patients diagnosed with ES-SCLC who undergo chemotherapy and prophylactic cranial irradiation still experience persistent intrathoracic disease. The prognosis for ES-SCLC is generally poor, and treatment focuses on providing palliative care. Without chemotherapy, the average survival time is only 8-10 weeks. However, approximately 70-80% of patients respond to chemotherapy, with 15-20% achieving complete responses. The median survival time with standard treatment regimens ranges from 8-11 months. Currently, the standard treatment approach for ES-SCLC involves administering four to six cycles of platinum-based chemotherapy, followed by prophylactic cranial irradiation for patients who respond to treatment. Despite initial response rates of 70-85% and complete response rates of up to 25% after chemotherapy, nearly all patients eventually experience disease relapse.

However, the current Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Imdelltra, Trilaciclib (G1T28), IN10018, BNT411, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Extensive-Stage Small-Cell Lung Cancer treatment. The key companies in the advanced development stage are Amgen, G1 Therapeutics, Inc., InxMed (Shanghai) Co., Ltd., BioNTech SE, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2023 to 2033.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.